165 related articles for article (PubMed ID: 15983552)
21. Twice weekly Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia.
Agrawal AK; Chang PP; Feusner J
J Pediatr Hematol Oncol; 2011 Jan; 33(1):e1-4. PubMed ID: 21102354
[TBL] [Abstract][Full Text] [Related]
22. Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we always follow the guidelines?
Redjoul R; Robin C; Foulet F; Leclerc M; Beckerich F; Cabanne L; di Blasi R; Pautas C; Toma A; Botterel F; Maury S; Cordonnier C
Bone Marrow Transplant; 2019 Jul; 54(7):1082-1088. PubMed ID: 30413810
[TBL] [Abstract][Full Text] [Related]
23. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.
Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K
Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597
[TBL] [Abstract][Full Text] [Related]
24. Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia.
Schrøder H; Agger KE; Rosthøj S; Carlsen NT; Schmiegelow K
Dan Med Bull; 2001 Nov; 48(4):275-7. PubMed ID: 11767129
[TBL] [Abstract][Full Text] [Related]
25. Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels.
Williams S; MacDonald P; Hoyer JD; Barr RD; Athale UH
Pediatr Blood Cancer; 2005 Jan; 44(1):55-62. PubMed ID: 15390276
[TBL] [Abstract][Full Text] [Related]
26. [Trimethoprim-sulfamethoxazole as antibacterial prophylaxis during induction therapy of children with acute lymphatic leukemia].
Agger KE; Schrøder H; Rosthøj S; Carlsen NT; Schmiegelow K
Ugeskr Laeger; 2002 Jan; 164(4):488-92. PubMed ID: 11838420
[TBL] [Abstract][Full Text] [Related]
27. Successful desensitization to dapsone for Pneumocystis carinii prophylaxis in an HIV-positive patient.
Cook DE; Kossey JL
Ann Pharmacother; 1998 Dec; 32(12):1302-5. PubMed ID: 9876811
[TBL] [Abstract][Full Text] [Related]
28. Benefits of sulfamethoxazole-trimethoprim prophylaxis on rates of sepsis after kidney transplant.
Horwedel TA; Bowman LJ; Saab G; Brennan DC
Transpl Infect Dis; 2014 Apr; 16(2):261-9. PubMed ID: 24621104
[TBL] [Abstract][Full Text] [Related]
29. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
[TBL] [Abstract][Full Text] [Related]
30. Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients.
Nickel P; Schürmann M; Albrecht H; Schindler R; Budde K; Westhoff T; Millward J; Suttorp N; Reinke P; Schürmann D
Infection; 2014 Dec; 42(6):981-9. PubMed ID: 25168263
[TBL] [Abstract][Full Text] [Related]
31. Recurrent Pneumocystis carinii colonization in a heart-lung transplant recipient on long-term trimethoprim-sulfamethoxazole prophylaxis.
Faul JL; Akindipe OA; Berry GJ; Doyle RL; Theodore J
J Heart Lung Transplant; 1999 Apr; 18(4):384-7. PubMed ID: 10226906
[TBL] [Abstract][Full Text] [Related]
32. Dual infection with Mycobacterium tuberculosis and Pneumocystis jiroveci Lymphadenitis in a Patient with HIV infection: case report and review of the literature.
Khawcharoenporn T; Apisarnthanarak A; Sakonlaya D; Mundy LM; Bailey TC
AIDS Patient Care STDS; 2006 Jan; 20(1):1-5. PubMed ID: 16426150
[TBL] [Abstract][Full Text] [Related]
33. Low-dose trimethoprim-sulfamethoxazole for Pneumocystis jiroveci pneumonia prophylaxis after allogeneic hematopoietic SCT.
Muto T; Takeuchi M; Kawaguchi T; Tanaka S; Tsukamoto S; Sakai S; Takeda Y; Abe D; Ohwada C; Sakaida E; Shimizu N; Yokote K; Iseki T; Nakaseko C
Bone Marrow Transplant; 2011 Dec; 46(12):1573-5. PubMed ID: 21243025
[No Abstract] [Full Text] [Related]
34. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy.
Chung JB; Armstrong K; Schwartz JS; Albert D
Arthritis Rheum; 2000 Aug; 43(8):1841-8. PubMed ID: 10943875
[TBL] [Abstract][Full Text] [Related]
35. Intermittent oral trimethoprim/sulfamethoxazole on two non-consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation.
Ohata Y; Ohta H; Hashii Y; Tokimasa S; Ozono K; Hara J
Pediatr Blood Cancer; 2009 Jan; 52(1):142-4. PubMed ID: 18819150
[TBL] [Abstract][Full Text] [Related]
36. Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer.
Caselli D; Petris MG; Rondelli R; Carraro F; Colombini A; Muggeo P; Ziino O; Melchionda F; Russo G; Pierani P; Soncini E; DeSantis R; Zanazzo G; Barone A; Cesaro S; Cellini M; Mura R; Milano GM; Meazza C; Cicalese MP; Tropia S; De Masi S; Castagnola E; Aricò M;
J Pediatr; 2014 Feb; 164(2):389-92.e1. PubMed ID: 24252793
[TBL] [Abstract][Full Text] [Related]
37. Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy.
Shankar SM; Nania JJ
Paediatr Drugs; 2007; 9(5):301-9. PubMed ID: 17927302
[TBL] [Abstract][Full Text] [Related]
38. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance.
Huang L; Crothers K; Atzori C; Benfield T; Miller R; Rabodonirina M; Helweg-Larsen J
Emerg Infect Dis; 2004 Oct; 10(10):1721-8. PubMed ID: 15504256
[TBL] [Abstract][Full Text] [Related]
39. Impact of prophylaxis choice on risk of pneumocystis pneumonia in children with cancer: A case-control study.
Geerlinks AV; Campigotto A; Science M; Gupta S
Eur J Cancer; 2020 Nov; 140():71-75. PubMed ID: 33059195
[TBL] [Abstract][Full Text] [Related]
40. [Successful prevention of Pneumocystis carinii infection with 1,920 mg of trimethoprim-sulfamethoxazole daily in patients with malignant hematopoietic diseases].
Lemez P; Rysková P; Votava V; Suchmová M; Jirásek A; Rubík I
Vnitr Lek; 1995 Oct; 41(10):688-91. PubMed ID: 8578700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
